Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Avastin Half Dose Demonstrates Similar Treatment Effect To Full Dose In NSCLC

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Results of Genentech’s AVAiL trial could potentially have an impact on physician prescribing patterns for bevacizumab.

You may also be interested in...



Avastin Misses Overall-survival Endpoint In Lung Cancer

Analysts expect minimal damage to sales as a result of AVAiL data.

Avastin Misses Overall-survival Endpoint In Lung Cancer

Analysts expect minimal damage to sales as a result of AVAiL data.

Genentech Resubmits Avastin sBLA For Metastatic Breast Cancer

The targeted oncologic is simultaneously approved in Europe for first-line treatment of patients with advanced non-small cell lung cancer.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

German HTA Queries Polivy Benefits Amid Lack Of Evidence

See All
UsernamePublicRestriction

Register

PS065666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By